- Agenus Inc. is set to unveil significant developments in cancer immunotherapy at a major conference in April 2025.
- Analyst forecasts suggest a potential upside of 236.54% for Agenus Inc. shares.
- GuruFocus estimates indicate an 85.58% potential upside based on the GF Value calculation.
Agenus Inc. (AGEN) is gearing up to present its cutting-edge advancements in cancer immunotherapy at the prestigious American Association for Cancer Research Annual Meeting in April 2025. This event will spotlight groundbreaking data from the NEOASIS trial and an exploratory Phase 1 study, focusing on the efficacy of botensilimab and balstilimab in combating advanced solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.